Trial Profile
A Phase 1, Open-label, Multi-center, Multiple-dose Study to Evaluate the Pharmacokinetics of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Telitacicept (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors RemeGen
- 16 Dec 2015 New trial record
- 04 Dec 2015 Results published in the Journal of Clinical Pharmacology